Cargando…

Estimation of Whole Body Radiation Exposure to Nuclear Medicine Personnel During Synthesis of (177)Lutetium-labeled Radiopharmaceuticals

PURPOSE OF THE STUDY: With rapid development in the field of nuclear medicine therapy, radiation safety of the personnel involved in synthesis of radiopharmaceuticals has become imperative. Few studies have been done on estimating the radiation exposure of personnel involved in the radio labeling of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arora, Geetanjali, Mishra, Rajesh, Kumar, Praveen, Yadav, Madhav, Ballal, Sanjana, Bal, Chandrasekhar, Damle, Nishikant Avinash
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5439194/ https://www.ncbi.nlm.nih.gov/pubmed/28533634 http://dx.doi.org/10.4103/0972-3919.202245

Ejemplares similares

Clinical Issues Related to Fluid Management during (177)Lu-Peptide Receptor Radionuclide Therapy in Metastatic Neuroendocrine Tumors with Carcinoid Heart Disease
por: Arora, Saurabh, et al.
Publicado: (2018)

Concomitant (177)Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
por: Yadav, Madhav Prasad, et al.
Publicado: (2019)

Long-term outcome of (177)Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients
por: Yadav, Madhav Prasad, et al.
Publicado: (2021)

Coexistence of Multiple Metastatic Lesions Showing Various Grades of Differentiation in a Single Patient with Neuroendocrine Tumor of Lung as Primary: A Combined Modality Approach of (68)Ga-DOTANOC Positron Emission Tomography/Computed Tomography and (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Imaging
por: Tripathy, Sarthak, et al.
Publicado: (2019)

Safety and Therapeutic Optimization of Lutetium-177 Based Radiopharmaceuticals
por: Ladrière, Typhanie, et al.
Publicado: (2023)

Stunning in post (131)I therapy scans after low-dose (131)I diagnostic whole body scans with differentiated thyroid cancer in the Indian patient population: Critical importance of interval between the two scans
por: Damle, Nishikant A., et al.
Publicado: (2012)

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System
por: Aslani, Alireza, et al.
Publicado: (2015)

[(177)Lu]Lu-DOTA-ZOL bone pain palliation in patients with skeletal metastases from various cancers: efficacy and safety results
por: Yadav, Madhav Prasad, et al.
Publicado: (2020)

Comparison of clinical outcome after a fixed dose versus dosimetry-based radioiodine treatment of Graves’ disease: Results of a randomized controlled trial in Indian population
por: Jaiswal, Abhishek Kumar, et al.
Publicado: (2014)

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)
por: Ballal, Sanjana, et al.
Publicado: (2021)

Vicarious visualization of gall bladder on Tc-99m ethylene dicysteine renal dynamic study
por: Arora, Geetanjali, et al.
Publicado: (2012)

Comparison between Two-sample Method with (99m)Tc-diethylenetriaminepentaacetic acid, Gates’ Method and Estimated Glomerular Filtration Rate Values by Formula Based Methods in Healthy Kidney Donor Population
por: Kumar, Manish, et al.
Publicado: (2017)

Role of Early Dynamic Positron Emission Tomography/Computed Tomography with 68Ga-prostate-specific Membrane Antigen-HBED-CC in Patients with Adenocarcinoma Prostate: Initial Results
por: Perveen, Gazala, et al.
Publicado: (2018)

Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study
por: Yadav, Madhav Prasad, et al.
Publicado: (2021)

Challenges and future options for the production of lutetium-177
por: Vogel, W. V., et al.
Publicado: (2021)

Lutetium Lu-177 Dotatate Flare Reaction
por: Salner, Andrew L., et al.
Publicado: (2020)

[(111)In]In/[(177)Lu]Lu-AAZTA(5)-LM4 SST(2)R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results
por: Nock, Berthold A., et al.
Publicado: (2023)

In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Inter-comparison of quantitative imaging of lutetium-177 ((177)Lu) in European hospitals
por: Wevrett, Jill, et al.
Publicado: (2018)

Prostate-specific Membrane Antigen Imaging in Recurrent Medullary Thyroid Cancer: A New Theranostic Tracer in the Offing?
por: Arora, Saurabh, et al.
Publicado: (2018)

Ribbing disease: Uncommon cause of a common symptom
por: Damle, Nishikant Avinash, et al.
Publicado: (2011)

Occurrence of symptomatic meningioma as a second neoplasm in patients with differentiated thyroid cancer treated with radioiodine
por: Damle, Nishikant Avinash, et al.
Publicado: (2012)

Can Early Dynamic Positron Emission Tomography/Computed Tomography Obviate the Need for Postdiuresis Image in (68)Ga-PSMA-HBED-CC Scan for Evaluation of Prostate Adenocarcinoma?
por: Perveen, Gazala, et al.
Publicado: (2018)

Lutetium-177-PSMA-617: A Vision of the Future
por: Chandran, Elias, et al.
Publicado: (2022)

Lutetium Lu 177 Vipivotide Tetraxetan: First Approval
por: Keam, Susan J.
Publicado: (2022)

Utility of single photon emission computed tomography/CT hybrid imaging over planar I-131 whole body scans in detection of adrenal metastases in differentiated thyroid cancer
por: Damle, Nishikant, et al.
Publicado: (2013)

Correction to: In vitro dose effect relationships of actinium‑225‑ and lutetium‑177‑labeled PSMA‑I&T
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
por: Meyer, Catherine, et al.
Publicado: (2022)

Ga-68 Prostate-Specific Membrane Antigen-HBED-CC Positron Emission Tomography/Computed Tomography in Anaplastic Thyroid Carcinoma
por: Subudhi, T. Kishan, et al.
Publicado: (2022)

Demonstration of 68Ga-prostate-specific Membrane Antigen Uptake in Metastatic Pancreatic Neuroendocrine Tumor
por: Prabhu, Meghana, et al.
Publicado: (2018)

Insulinoma - The incremental value of somatostatin receptor positron emission tomography
por: Arunraj, S. T., et al.
Publicado: (2017)

Neuroendocrine Tumor Therapy with Lutetium-177: A Literature Review
por: Maqsood, Muhammad Haisum, et al.
Publicado: (2019)

Lutetium-177 Dotatate-Induced Hemolytic Anemia and Myelodysplastic Syndrome
por: Alkassis, Samer, et al.
Publicado: (2022)

Graves' Ophthalmopathy on (68)Ga-DOTANOC Positron Emission Tomography/Computed Tomography
por: Arora, Saurabh, et al.
Publicado: (2019)

A curious case of refractory hypothyroidism due to selective malabsorption of oral thyroxine
por: Damle, Nishikant, et al.
Publicado: (2012)

Inguinal node metastasis from follicular thyroid cancer
por: Damle, Nishikant, et al.
Publicado: (2013)

Retinoic acid therapy in patients with radioiodine negative differentiated thyroid cancer and clinical or biochemical evidence of disease: An initial experience
por: Damle, Nishikant, et al.
Publicado: (2011)

Comparative Radioimmunotherapy of Experimental Melanoma with Novel Humanized Antibody to Melanin Labeled with 213Bismuth and 177Lutetium
por: Allen, Kevin J. H., et al.
Publicado: (2019)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives
por: Seitzer, Konstantin Egon, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_d9rqvadkpac8c6r7vv7aq6temd